Company: SCLXW
Filing Date: 2025-08-21
Form Type: 424B3
Source: 0001193125-25-184626
Chunk: 5

Company: Scilex Holding Co
Filing Date: 2025-08-21
Form: 424B3
Chunk 5
---
 1, 2023, the Company has entered into the following transactions in which Dr. Ji may be deemed to have a direct or indirect material
interest, based on his role as an executive officer and director of Sorrento Therapeutics, Inc. (which is a counter-party to the below-referenced transactions) at the time such transactions were entered into.

2

On September 12, 2022, Vickers entered into the Stockholder Agreement with Sorrento (the “Stockholder Agreement”).

Pursuant to the terms of the Stockholder Agreement, from and after its effectiveness, and for so long as Sorrento together with its affiliates, subsidiaries,
successors and assigns (other than the Company and its subsidiaries) (the “Sorrento Group”) beneficially owns any shares of Series A Preferred Stock, among other things, (i) Sorrento had the right, but not the obligation, to
designate each director to be nominated, elected or appointed to the Board (each, a “Stockholder Designee” and collectively, the “Stockholder Designees”), regardless of whether such Stockholder Designee is to be elected to
the Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized
number of members of the Board or the size of the Board and (ii) the Company were required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected
or appointed to the Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties previously agreed that the Board will continue to satisfy all applicable stock exchange requirements applicable to directors,
including with respect to director independence. Sorrento also had the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the right to appoint a representative of Sorrento to attend all
meetings of the committees of the Board.

The Stockholder Agreement also provided that the Company shall not, and shall cause its subsidiaries not to,
among others, without the prior written consent of Sorrento: (i) amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate
of Designations of Series A Preferred Stock